User profiles for V. M. Lauschke
 | Volker LauschkeFull Professor, Karolinska Institutet; Deputy Head, IKP Verified email at ki.se Cited by 8155 |
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting
…, TE Klein, VM Lauschke… - Clinical …, 2016 - Wiley Online Library
This article provides nomenclature recommendations developed by an international workgroup
to increase transparency and standardization of pharmacogenetic (PGx) result reporting. …
to increase transparency and standardization of pharmacogenetic (PGx) result reporting. …
Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates
VM Lauschke, DFG Hendriks, CC Bell… - Chemical research in …, 2016 - ACS Publications
The liver is an organ with critical importance for drug treatment as the disposition and response
to a given drug is often determined by its hepatic metabolism. Patient-specific factors can …
to a given drug is often determined by its hepatic metabolism. Patient-specific factors can …
[HTML][HTML] Pharmacogenomic biomarkers for improved drug therapy—recent progress and future developments
Much of the inter-individual variability in drug efficacy and risk of adverse reactions is due to
polymorphisms in genes encoding proteins involved in drug pharmacokinetics and …
polymorphisms in genes encoding proteins involved in drug pharmacokinetics and …
[HTML][HTML] Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease
…, NR Kitteringham, CEP Goldring, VM Lauschke… - Scientific reports, 2016 - nature.com
Liver biology and function, drug-induced liver injury (DILI) and liver diseases are difficult to
study using current in vitro models such as primary human hepatocyte (PHH) monolayer …
study using current in vitro models such as primary human hepatocyte (PHH) monolayer …
Worldwide distribution of cytochrome P450 alleles: a meta‐analysis of population‐scale sequencing projects
…, VM Lauschke - Clinical Pharmacology …, 2017 - Wiley Online Library
Genetic polymorphisms in cytochrome P450 (CYP) genes can result in altered metabolic
activity toward a plethora of clinically important medications. Thus, single nucleotide variants …
activity toward a plethora of clinically important medications. Thus, single nucleotide variants …
Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
…, PJ Richardson, V Monteil, VM Lauschke… - EMBO molecular …, 2020 - embopress.org
Baricitinib is an oral Janus kinase ( JAK )1/ JAK 2 inhibitor approved for the treatment of
rheumatoid arthritis ( RA ) that was independently predicted, using artificial intelligence ( AI ) …
rheumatoid arthritis ( RA ) that was independently predicted, using artificial intelligence ( AI ) …
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality
…, A Mirazimi, P Abizanda, VM Lauschke - Science …, 2021 - science.org
Using AI, we identified baricitinib as having antiviral and anticytokine efficacy. We now show
a 71% (95% CI 0.15 to 0.58) mortality benefit in 83 patients with moderate-severe SARS-…
a 71% (95% CI 0.15 to 0.58) mortality benefit in 83 patients with moderate-severe SARS-…
Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study
CC Bell, ACA Dankers, VM Lauschke… - Toxicological …, 2018 - academic.oup.com
Primary human hepatocytes (PHHs) are commonly used for in vitro studies of drug-induced
liver injury. However, when cultured as 2D monolayers, PHH lose crucial hepatic functions …
liver injury. However, when cultured as 2D monolayers, PHH lose crucial hepatic functions …
[HTML][HTML] Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug …
M Kozyra, M Ingelman-Sundberg, VM Lauschke - Genetics in Medicine, 2017 - Elsevier
Purpose In this study we characterized the genetic variability of 146 clinically relevant genes
influencing drug pharmacokinetics in African and European subpopulations, which are key …
influencing drug pharmacokinetics in African and European subpopulations, which are key …
[HTML][HTML] Integrating rare genetic variants into pharmacogenetic drug response predictions
…, S Mkrtchian, Y Zhou, VM Lauschke - Human genomics, 2018 - Springer
Background Variability in genes implicated in drug pharmacokinetics or drug response can
modulate treatment efficacy or predispose to adverse drug reactions. Besides common …
modulate treatment efficacy or predispose to adverse drug reactions. Besides common …